SynthesisBMC cancer2026
Prognostic role of HSPs in human colorectal cancer: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHeat shock proteins (HSPs) play pivotal roles in cellular stress responses and are associated with the progression and treatment resistance of various cancers. They are also critically important in the occurrence, development, and prognosis of colorectal cancer (CRC). However, the specific prognostic value of HSPs in CRC remains controversial. This study aimed to conduct a meta-analysis to evaluate the prognostic significance of HSPs in CRC patients.
methodsLiterature searches were conducted in the PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and China Biology Medicine (CBM) databases up to March 15, 2026. Data regarding the relationship between the expression of HSPs and survival outcomes were extracted. The pooled hazard ratio (HR) with a 95% confidence interval (CI) was calculated.
resultsWe included 42 studies involving a total of 8,142 CRC patients. The results indicated that elevated levels of HSPs were associated with a poorer survival prognosis in CRC patients (HR = 1.78, 95% CI [1.48, 2.14]; p < 0.001). Subgroup analysis of overall survival revealed that high levels of HSP27 (HR = 1.72, 95% CI [1.23, 2.41]), HSP47 (HR = 2.43, 95% CI [1.82, 3.24]), HSP70 (HR = 2.14, 95% CI [1.74, 2.63]), and HSP90 (HR = 2.02, 95% CI [1.31, 3.14]) were significantly associated with a poorer survival prognosis in CRC patients(p < 0.05 for all comparisons).
conclusionThis meta-analysis highlights the significant role of HSPs in the prognostic evaluation of CRC patients. Elevated levels of HSP27, HSP47, HSP70, and HSP90 are identified as crucial biomarkers indicative of poor prognosis in CRC patients, with particularly noteworthy associations between high expression levels of HSP47 and HSP70 and adverse outcomes in CRC. While some heterogeneity was noted in the analysis, the results of the subgroup analysis reinforce the involvement of specific HSP family members in tumor progression. To further substantiate the independent prognostic value of HSPs and to investigate their potential as therapeutic targets for CRC, future studies should be rigorously designed, standardized, and conducted on a large scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.